Replies to post #134 on Zyla Life Sciences (fka ZCOR)

[EM]

http://seekingalpha.com/pr/16658074-egalet-reports-third-quarter-2016-financial-results

"Much progress was made in the third quarter with the successful FDA Advisory Committee meeting for ARYMO ER and the closing of a $40 million financing with a potential additional $40 million upon ARYMO ER approval," said Bob Radie, president and chief executive officer of Egalet. "We are now focused on working closely with the FDA to complete the regulatory review of ARYMO ER and preparing for a potential launch in the first quarter of 2017."

Cash Position: As of September 30, 2016, Egalet had cash and marketable securities totaling $101.2 million.